CLDX: financial statements from SEC — TradeAlmanac

CLDX

Celldex Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Mar 2026	30 Sept 2025	30 Jun 2025	31 Mar 2025	30 Sept 2024	30 Jun 2024
Revenue	15,000	—	730,000	695,000	3M	2M
Research and development	73M	63M	54M	53M	45M	40M
Selling, general and administrative	11M	11M	10M	11M	10M	9M
Operating expenses	84M	74M	65M	63M	55M	49M
Operating income	−84M	−74M	−64M	−63M	−52M	−46M
Net income	−79M	−67M	−57M	−54M	−42M	−36M
Earnings per share	−1.18	−1.01	−0.85	−0.81	−0.64	−0.54
Earnings per share, diluted	−1.18	−1.01	−0.85	−0.81	−0.64	−0.54
Weighted average shares	67M	66,420	66,392	66,383	66,294	66,019
Weighted average shares, diluted	67M	66,420	66,392	66,383	66,294	66,019

Balance sheet

Metric	31 Mar 2026	31 Dec 2025	30 Sept 2025	30 Jun 2025	31 Mar 2025	31 Dec 2024	30 Sept 2024	30 Jun 2024
Cash and equivalents	36M	29M	36M	23M	17M	28M	36M	43M
Short-term investments	416M	490M	547M

Cash flow

Metric	31 Mar 2026	31 Mar 2025
Operating cash flow	−66M	−54M
Depreciation and amortisation	854,000	867,000
Share-based compensation	9M	9M
Capital expenditure	2M	265,000
Investing cash flow	72M	43M
Financing cash flow	327,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator